News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Subscribe To Our Newsletter & Stay Updated
